These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38752732)

  • 1. Breakthrough Invasive Fungal Infections in Patients With High-Risk Hematological Disorders Receiving Voriconazole and Posaconazole Prophylaxis: A Systematic Review.
    Boutin CA; Durocher F; Beauchemin S; Ziegler D; Abou Chakra CN; Dufresne SF
    Clin Infect Dis; 2024 Jul; 79(1):151-160. PubMed ID: 38752732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis.
    Biehl LM; Vehreschild JJ; Liss B; Franke B; Markiefka B; Persigehl T; Bücker V; Wisplinghoff H; Scheid C; Cornely OA; Vehreschild MJ
    J Antimicrob Chemother; 2016 Sep; 71(9):2634-41. PubMed ID: 27317443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world assessment of the effectiveness of posaconazole for the prophylaxis and treatment of invasive fungal infections in hematological patients: A retrospective observational study.
    Chen X; Wang J; Wang S; Jin J; Li J; Gao S; Li J; Li J; Liu Q; Hu Y; Lin D; Sun Z; Yang J; Hu J; Wu X; Huang X; Shao Z; Deng Q; Wang C; Liu L; Chen H; Wang J; Wei X; Shen J; Zhang X; Wu D
    Medicine (Baltimore); 2021 Jul; 100(30):e26772. PubMed ID: 34397725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome.
    Phillips K; Cirrone F; Ahuja T; Siegfried J; Papadopoulos J
    J Oncol Pharm Pract; 2019 Mar; 25(2):398-403. PubMed ID: 30319061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Breakthrough of invasive fungal disease with posaconazole as primary prophylaxis after induction chemotherapy for acute myeloid leukemia].
    Pei RZ; Lu Y; Zhang PS; Liu XH; Chen D; Du XH; Sha KY; Li SY; Cao JJ; Chen LG; Zhuang XX; Tang SH
    Zhonghua Nei Ke Za Zhi; 2020 Mar; 59(3):213-217. PubMed ID: 32146748
    [No Abstract]   [Full Text] [Related]  

  • 6. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study.
    Auberger J; Lass-Flörl C; Aigner M; Clausen J; Gastl G; Nachbaur D
    J Antimicrob Chemother; 2012 Sep; 67(9):2268-73. PubMed ID: 22653819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Antifungal Prophylaxis Drugs in Patients With Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Network Meta-analysis.
    Wang J; Zhou M; Xu JY; Zhou RF; Chen B; Wan Y
    JAMA Netw Open; 2020 Oct; 3(10):e2017652. PubMed ID: 33030550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies.
    Hachem R; Assaf A; Numan Y; Shah P; Jiang Y; Chaftari AM; Raad II
    Int J Antimicrob Agents; 2017 Sep; 50(3):384-388. PubMed ID: 28694233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Posaconazole Serum Concentrations from Delayed-Release Tablets in Patients at High Risk for Fungal Infections.
    Chin A; Pergam SA; Fredricks DN; Hoofnagle AN; Baker KK; Jain R
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.
    Solano C; Slavin M; Shaul AJ; Marks DI; Cordonnier C; Cornely OA; Pagliuca A; Cragin L; Jarque I; Garcia-Vidal C; Sorensen S; Vanness DJ; Charbonneau C; Barrueta JA; Peral C; De Salas-Cansado M; Bow EJ
    Mycoses; 2017 Feb; 60(2):79-88. PubMed ID: 27562016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-utility analysis of antifungal prophylaxis for invasive fungal infections in acute myeloid leukaemia patients receiving chemotherapy: a study from a middle-income country.
    Pungprasert T; Dhirachaikulpanich D; Phutthasakda W; Tantai N; Maneeon S; Nganthavee V; Atipas K; Tanpong S; Krithin S; Tanglitanon S; Jutidamrongphan W; Chayakulkeeree M; Srinonprasert V; Phikulsod P
    J Hosp Infect; 2024 Mar; 145():118-128. PubMed ID: 38219835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients.
    Fontana L; Perlin DS; Zhao Y; Noble BN; Lewis JS; Strasfeld L; Hakki M
    Clin Infect Dis; 2020 Feb; 70(5):723-730. PubMed ID: 30958538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole.
    Scott SA; Perry C; Mahmoudjafari Z; Martin GA; Boyd S; Thompson J; Thomas B
    Transpl Infect Dis; 2023 Apr; 25(2):e14045. PubMed ID: 36856447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing Epidemiology of Invasive Mold Infections in Patients Receiving Azole Prophylaxis.
    Lamoth F; Chung SJ; Damonti L; Alexander BD
    Clin Infect Dis; 2017 Jun; 64(11):1619-1621. PubMed ID: 28199491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.
    Tverdek FP; Heo ST; Aitken SL; Granwehr B; Kontoyiannis DP
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspergillus fumigatus-a systematic review to inform the World Health Organization priority list of fungal pathogens.
    Morrissey CO; Kim HY; Duong TN; Moran E; Alastruey-Izquierdo A; Denning DW; Perfect JR; Nucci M; Chakrabarti A; Rickerts V; Chiller TM; Wahyuningsih R; Hamers RL; Cassini A; Gigante V; Sati H; Alffenaar JW; Beardsley J
    Med Mycol; 2024 Jun; 62(6):. PubMed ID: 38935907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia.
    Tu S; Zhang K; Wang N; Chu J; Yang L; Xie Z
    Sci Rep; 2023 Nov; 13(1):18789. PubMed ID: 37914820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of invasive fungal diseases between patients with acute myeloid leukemia receiving posaconazole prophylaxis and those not receiving prophylaxis: A single-center, observational, case-control study in South Korea.
    Yang E; Choi EJ; Park HS; Lee SO; Choi SH; Kim YS; Lee JH; Lee JH; Lee KH; Kim SH
    Medicine (Baltimore); 2021 May; 100(20):e25448. PubMed ID: 34011022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Voriconazole prophylaxis in leukemic patients: A retrospective single-center study.
    Bui V; Walker SA; Elligsen M; Vyas A; Kiss A; Palmay L
    J Oncol Pharm Pract; 2020 Jun; 26(4):873-881. PubMed ID: 31566111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients with invasive fungal infection.
    Pepeler MS; Yildiz Ş; Yegin ZA; Özkurt ZN; Tunçcan ÖG; Erbaş G; Köktürk N; Kalkanci A; Yildirim Z
    J Infect Dev Ctries; 2018 Sep; 12(9):799-805. PubMed ID: 31999640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.